A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Nanovis Announces Alpha Launch of the 1st & Only Bioceramic Nanotube-Enhanced Pedicle Screw System, Nano FortiFix®

First use of a nanotechnology enhanced pedicle screw with label claims to increase and accelerate human osteoblast and mesenchymal stem cell calcified extracellular matrix production in vitro

Nanovis, an award-winning technology company with unique and differentiated nanotechnology surfaces for improving bone growth and fighting infection, is pleased to announce the first implantations of its Bioceramic Nanotube-Enhanced pedicle screw system, Nano FortiFix, the only nanotechnology designated titanium-surfaced pedicle screw.

Nano FortiFix pedicle screws are designed with a proprietary and patent protected bio-ceramic nanotube surface. Unlike other technologies, Nanovis’s bioceramic nanotubes were granted a nanotechnology designation with specific label language stating “The nanotube arrays have been shown to increase and accelerate calcified extracellular matrix production in vitro”. The Nano FortiFix label also includes statistically significantly superior human osteoblast and mesenchymal stem cell calcified extracellular matrix production data compared to other surfaces.

“This nanotechnology label and accompanying comparative data provides unusual clarity for surgeons and hospital contracting executives when selecting a technology that is unequivocally differentiated for their patients seeking the best care,” says Matt Hedrick, Nanovis CEO.

Nanovis was the first company to receive nanotechnology designation for PEEK enhanced titanium interbodies and is the first and only company to receive nanotechnology designation for titanium-surfaced pedicle screws.

“I’m pleased to now have a pedicle screw system with cutting edge nanotechnology to offer my patients. I’ve been using Nano FortiFix pedicle screws in combination with Nano FortiCore interbodies, giving my patients a  fusion using 360˚ nanotechnology. It’s exciting that nanotechnology is no longer limited to the interbody space,” says Alan McGee MD of Parkview Health in Fort Wayne, IN.

“Nanovis is pleased with the success of this alpha launch. The feedback from innovative and discerning surgeons and distributors has been positive, encouraging, and primes us for the full commercial launch of our open and MIS systems,” says Jeff Shepherd, Nanovis Vice President of Sales.

This is Nanovis’ 5th implant system cleared with a bioceramic nanotube surface establishing a well understood regulatory pathway. Nanovis’ commitment to help reduce the pain and suffering from implant loosening has never been higher and we are grateful to the surgeons, scientists, and employees that have created such a powerful combination of technology-enhanced systems.

Nanovis is actively expanding distribution for bioceramic nanotube enhanced Nano FortiCore interbodies and Nano FortiFix pedicle screws.

SourceNanovis
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy